CEO, Currus Biologics
Stories naming Sam Cobb. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.
Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.